Free Trial
NASDAQ:BTMD

biote (BTMD) Stock Price, News & Analysis

biote logo
$5.09 -0.44 (-7.96%)
As of 01/31/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About biote Stock (NASDAQ:BTMD)

Key Stats

Today's Range
$4.79
$5.33
50-Day Range
$5.09
$6.93
52-Week Range
$3.79
$8.44
Volume
401,560 shs
Average Volume
86,436 shs
Market Capitalization
$276.59 million
P/E Ratio
19.58
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

biote Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
59th Percentile Overall Score

BTMD MarketRank™: 

biote scored higher than 59% of companies evaluated by MarketBeat, and ranked 495th out of 957 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    biote has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    biote has only been the subject of 1 research reports in the past 90 days.

  • Read more about biote's stock forecast and price target.
  • Earnings Growth

    Earnings for biote are expected to decrease by -28.00% in the coming year, from $0.75 to $0.54 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of biote is 19.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 102.15.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of biote is 19.58, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 58.44.

  • Read more about biote's valuation and earnings.
  • Percentage of Shares Shorted

    2.61% of the float of biote has been sold short.
  • Short Interest Ratio / Days to Cover

    biote has a short interest ratio ("days to cover") of 5.8.
  • Change versus previous month

    Short interest in biote has recently decreased by 3.14%, indicating that investor sentiment is improving.
  • Dividend Yield

    biote does not currently pay a dividend.

  • Dividend Growth

    biote does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.61% of the float of biote has been sold short.
  • Short Interest Ratio / Days to Cover

    biote has a short interest ratio ("days to cover") of 5.8.
  • Change versus previous month

    Short interest in biote has recently decreased by 3.14%, indicating that investor sentiment is improving.
  • News Sentiment

    biote has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for biote this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for BTMD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added biote to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, biote insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.90% of the stock of biote is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 21.68% of the stock of biote is held by institutions.

  • Read more about biote's insider trading history.
Receive BTMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for biote and its competitors with MarketBeat's FREE daily newsletter.

BTMD Stock News Headlines

Truist Financial Reaffirms Their Buy Rating on biote (BTMD)
Roth MKM Sticks to Its Buy Rating for biote (BTMD)
Is this Elon’s true agenda?
All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors have all turned to my business partner and I for our thoughts on the market. And with every investor in America wondering what Elon is going to do now that he's in Washington, this is what we tell them
Biote announces CEO succession plan
Biote Names Christensen as CEO Upon Weber's Retirement
Biote Announces CEO Retirement and Succession Plan
Craig-Hallum Keeps Their Buy Rating on biote (BTMD)
See More Headlines

BTMD Stock Analysis - Frequently Asked Questions

biote's stock was trading at $6.18 at the beginning of the year. Since then, BTMD stock has decreased by 17.6% and is now trading at $5.09.
View the best growth stocks for 2025 here
.

biote Corp. (NASDAQ:BTMD) posted its quarterly earnings data on Thursday, August, 10th. The company reported $0.44 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.34. The company earned $49.26 million during the quarter, compared to the consensus estimate of $46.76 million. biote had a negative trailing twelve-month return on equity of 32.41% and a net margin of 5.20%.

Top institutional investors of biote include Kanen Wealth Management LLC (0.53%), Sanders Morris Harris LLC (0.10%), Rhumbline Advisers (0.07%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Roystone Capital Management Lp, Mary Elizabeth Conlon, Robert Charles Peterson and Samar Jagat Kamdar.
View institutional ownership trends
.

Shares of BTMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that biote investors own include Meta Platforms (META), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V) and Netflix (NFLX).

Company Calendar

Last Earnings
8/10/2023
Today
2/01/2025
Next Earnings (Estimated)
3/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Medicinals & botanicals
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BTMD
Employees
194
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$12.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+96.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$3.32 million
Pretax Margin
5.99%

Debt

Sales & Book Value

Annual Sales
$185.36 million
Cash Flow
$0.45 per share
Book Value
($0.58) per share

Miscellaneous

Free Float
46,784,000
Market Cap
$276.59 million
Optionable
Not Optionable
Beta
1.08
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:BTMD) was last updated on 2/1/2025 by MarketBeat.com Staff
From Our Partners